

# Memory CD8 T Cells Generated by Cytomegalovirus Vaccine Vector Expressing NKG2D Ligand Have Effector-Like Phenotype and Distinct Functional Features

---

Šustić, Marko; Cokarić Brdovčak, Maja; Lisnić, Berislav; Materljan, Jelena; Juranić Lisnić, Vanda; Rožmanić, Carmen; Indenbirken, Daniela; Hiršl, Lea; Busch, Dirk H.; Brizić, Ilija; ...

Source / Izvornik: **Frontiers in Immunology, 2021, 12**

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.3389/fimmu.2021.681380>

Permanent link / Trajna poveznica: <https://urn.nsk.hr/urn:nbn:hr:184:519193>

Rights / Prava: [Attribution 4.0 International](#)/[Imenovanje 4.0 međunarodna](#)

Download date / Datum preuzimanja: **2025-03-12**



Repository / Repozitorij:

[Repository of the University of Rijeka, Faculty of Medicine - FMRI Repository](#)





# Memory CD8 T Cells Generated by Cytomegalovirus Vaccine Vector Expressing NKG2D Ligand Have Effector-Like Phenotype and Distinct Functional Features

Marko Štutić<sup>1</sup>, Maja Cokarić Brdovčak<sup>2</sup>, Berislav Lisnić<sup>2</sup>, Jelena Materljan<sup>1</sup>, Vanda Juranić Lisnić<sup>2</sup>, Carmen Rožmanić<sup>2</sup>, Daniela Indenbirken<sup>3</sup>, Lea Hiršl<sup>2</sup>, Dirk H. Busch<sup>4,5</sup>, Ilija Brzić<sup>2</sup>, Astrid Krmpotić<sup>1</sup> and Stipan Jonjić<sup>1,2\*</sup>

## OPEN ACCESS

### Edited by:

Ramon Arens,  
Leiden University Medical Center,  
Netherlands

### Reviewed by:

Chris Benedict,  
La Jolla Institute for Immunology  
(LJI), United States  
Matthew Parsons,  
Emory University, United States

### \*Correspondence:

Stipan Jonjić  
stipan.jonjic@medri.uniri.hr

### Specialty section:

This article was submitted to  
Viral Immunology,  
a section of the journal  
Frontiers in Immunology

**Received:** 16 March 2021

**Accepted:** 12 May 2021

**Published:** 03 June 2021

### Citation:

Štutić M, Cokarić Brdovčak M, Lisnić B, Materljan J, Juranić Lisnić V, Rožmanić C, Indenbirken D, Hiršl L, Busch DH, Brzić I, Krmpotić A and Jonjić S (2021) Memory CD8 T Cells Generated by Cytomegalovirus Vaccine Vector Expressing NKG2D Ligand Have Effector-Like Phenotype and Distinct Functional Features. *Front. Immunol.* 12:681380. doi: 10.3389/fimmu.2021.681380

<sup>1</sup> Department of Histology and Embryology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia, <sup>2</sup> Center for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia, <sup>3</sup> Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany, <sup>4</sup> Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München (TUM), Munich, Germany, <sup>5</sup> German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany

Viral vectors have emerged as a promising alternative to classical vaccines due to their great potential for induction of a potent cellular and humoral immunity. Cytomegalovirus (CMV) is an attractive vaccine vector due to its large genome with many non-essential immunoregulatory genes that can be easily manipulated to modify the immune response. CMV generates a strong antigen-specific CD8 T cell response with a gradual accumulation of these cells in the process called memory inflation. In our previous work, we have constructed a mouse CMV vector expressing NKG2D ligand RAE-1 $\gamma$  in place of its viral inhibitor m152 (RAE-1 $\gamma$ MCMV), which proved to be highly attenuated *in vivo*. Despite attenuation, RAE-1 $\gamma$ MCMV induced a substantially stronger CD8 T cell response to vectored antigen than the control vector and provided superior protection against bacterial and tumor challenge. In the present study, we confirmed the enhanced protective capacity of RAE-1 $\gamma$ MCMV as a tumor vaccine vector and determined the phenotypical and functional characteristics of memory CD8 T cells induced by the RAE-1 $\gamma$  expressing MCMV. RNAseq data revealed higher transcription of numerous genes associated with effector-like CD8 T cell phenotype in RAE-1 $\gamma$ MCMV immunized mice. CD8 T cells primed with RAE-1 $\gamma$ MCMV were enriched in TCF1 negative population, with higher expression of KLRG1 and lower expression of CD127, CD27, and Eomes. These phenotypical differences were associated with distinct functional features as cells primed with RAE-1 $\gamma$ MCMV showed inferior cytokine-producing abilities but comparable cytotoxic potential. After adoptive transfer into naive hosts, OT-1 cells induced with both RAE-1 $\gamma$ MCMV and the control vector were equally efficient in rejecting established tumors, suggesting the context of latent infection and cell numbers as important determinants of enhanced anti-tumor response following RAE-1 $\gamma$ MCMV vaccination. Overall, our results

shed new light on the phenotypical and functional distinctness of memory CD8 T cells induced with CMV vector expressing cellular ligand for the NKG2D receptor.

**Keywords:** memory T cells, CD8 T lymphocytes, cytomegalovirus, vaccine vector, tumor vaccine, Klrg1, TCF1

## INTRODUCTION

In recent decades, various attempts have been made to harness the body's immune system in the fight against neoplastic cells by modulating various stages of the "cancer-immunity cycle" (1). Live replicating viral vectors, genetically engineered to express tumor epitopes, have a great potential in inducing potent and long-lasting cellular immunity against malignant cells. In this respect, cytomegalovirus (CMV) represents a particularly attractive viral vector candidate due to its life-long persistence and strong capacity to induce antigen-specific CD8 T cells, which gradually accumulate in the host (2). Moreover, CMV possesses many immunomodulatory genes that can be manipulated to modulate the immune response against viral or vectored epitopes (3).

RAE-1 $\gamma$  is a ligand of NKG2D, an activating receptor expressed on various immune cells, including NK and CD8 T cells (4). In our previous research, we have constructed a mouse CMV vector expressing RAE-1 $\gamma$  in place of its viral inhibitor m152 (RAE-1 $\gamma$ MCMV). This vector proved to be highly attenuated *in vivo* in both BALB/c and C57BL/6J mice (5). Furthermore, co-expression of foreign CD8 T-cell epitope with RAE-1 $\gamma$  in CMV vector induced an augmented CD8 T cell response (6). When tested in the murine melanoma model, the MCMV vector expressing RAE-1 $\gamma$  and tumor antigen proved to be superior in delaying melanoma growth compared to the control vector (7). However, the mechanisms conferring this increased protection remained unclear.

The memory population of CD8 T cells consists of three major subsets: central memory (T<sub>cm</sub>), effector memory cells (T<sub>em</sub>), and tissue-resident memory cells (T<sub>rm</sub>). T<sub>cm</sub> express CD62L and CCR7, transcription factors Eomes and TCF1 and are thought to have enhanced proliferative capabilities with low cytotoxic potential. On the other hand, T<sub>em</sub> lack CD62L and CCR7 expression, express T-bet and Blimp 1 transcription factors, and are associated with lower proliferative capabilities but are considered to be highly cytotoxic (8–10). Further work identified subpopulation in the T<sub>em</sub> compartment of effector-like cells expressing KLRG1 and conferring greater protective capabilities in certain models of infection (11, 12). However, this division based on a handful of molecules has come under intense scrutiny, as the advances of single-cell sequencing technologies and mass cytometry showed memory CD8 T cells to be more heterogeneous than previously thought (13).

This study confirmed the superiority of MCMV vector expressing RAE-1 $\gamma$  in conferring protection against subcutaneous tumor challenge in both prophylactic and therapeutic settings. RAE-1 $\gamma$ MCMV induced substantially higher numbers of epitope-specific memory CD8 T cells, which had a highly differentiated, effector-like transcriptional profile.

The majority of these cells lacked the expression of the TCF1 transcription factor, produced lower amounts of cytokines but exhibited similar cytotoxic capabilities compared to OT-1 cells primed with the control vector. Overall, our study revealed that the insertion of RAE-1 $\gamma$  into the CMV vector leads to gross differences in transcriptomic, phenotypical, and functional profiles of memory CD8 T cells.

## METHODS

### Mice, Viruses, Tumor Cell Lines and *In Vivo* Depletion

C57BL/6J, OT-1 (3831), *CD4<sup>cre</sup>* and *Klrk1<sup>fl/fl</sup>* mice were housed and bred under specific pathogen-free conditions at the Central Animal Facility, Faculty of Medicine, University of Rijeka, under the guidelines contained in the International Guiding Principles for Biomedical Research Involving Animals. *CD4<sup>cre</sup>* mice were kindly provided by D. Littman. *Klrk1<sup>fl/fl</sup>* mice were generated as described previously (14). Adult female mice (6–12 weeks old) were strictly age-matched for use in experiments. The Ethics Committee at the Faculty of Medicine, Rijeka and Ethics Committee of the Veterinary Department of the Ministry of Agriculture, Croatia approved all experiments.

MCMV-SIINFEKL and RAE-1 $\gamma$ MCMV-SIINFEKL were constructed as described previously (6, 15). Virus stocks were prepared as previously described (16). Mice were immunized with  $2 \times 10^5$  PFU in the final volume of 50  $\mu$ L DMEM *via* footpad (f.p.) route of injection.

E.G7-OVA cell line was kindly provided by V. Sexl (Vetmeduni, Vienna). Cells were cultured in RPMI 1640 (10% FCS) supplemented with G418 (Geneticin, Invivogen). B16-OVA cell line was kindly provided by T. Sparwasser (TWINCORE, Hannover) and cells were cultured in DMEM (10% FCS) also supplemented with G418.  $10^6$  E.G7-OVA and  $10^5$  B16-OVA cells were inoculated subcutaneously into an animal's right flank in 100  $\mu$ L PBS. Tumor growth was measured using digital caliper two-three times a week, and mice were sacrificed when tumors reached approximately 1000<sup>3</sup> mm for ethical reasons.

*In vivo* CD8 T cell depletion was performed by i.p. injection of 150  $\mu$ g of anti-CD8 antibody (YTS 169.4). Antibodies were administered once a week, over a period of 8 weeks.

### Flow Cytometry

Flow cytometry was performed according to the *Guidelines for the use of flow cytometry and cell sorting in immunological studies* (17). Splenocytes were isolated using a standard protocol. Briefly, mice were sacrificed, spleens harvested, and homogenized,

followed by erythrocyte lysis. Blood samples were collected from a saphenous vein, followed by erythrocyte lysis. After leukocyte isolation, Fc receptors were blocked using a 2.4G2 antibody. For surface staining following antibodies were used: CD8 $\alpha$  PerCP-Cy5.5 or SB780 (clone: 53-6.7; 1:400 or 1:200), CD45.1 e450 (clone: A20; 1:400), KLRG1 PE-e610 (clone:2F1, 1:100), CD127 APC (clone: SB/199, 1:100), CD44 A700 (clone: IM7, 1:100), PD1 PerCP-e710 (clone: RMP1-30; 1:200), TIM3 PE-Cy7 (clone: RMT3-23; 1:100), CD27 PE-Cy7 (clone: LG.7F9; 1:200) and CD107a eF660 (clone: 1D4B; 1:400). Fixable Viability Dye (eBioscience) was used to exclude dead cells. For intracellular staining Intracellular fixation and permeabilization buffer set (eBioscience) was used along with following intracellular antibodies: IFN $\gamma$  FITC (clone: XMG1.2; 1:100), TNF $\alpha$  PE-e610 (clone: MP6-XT22; 1:100), IL-2 PE-Cy7 (clone: JES6-5H4; 1:100), Granzyme B PE (clone: NGZB; 1:100). For transcription factor staining eBioscience Foxp3/Transcription Staining Buffer Set was used with: TCF1 A488 (clone:C63D9; 1:400), TOX PE (clone: TXRX10; 1:100), T-bet PerCP-Cy5.5 (clone:4B10; 1:400) and EOMES PE (clone:Dan11mag; 1:100). Antibody against TCF1 was produced by Cell Signaling Technology, and Invitrogen produced all other antibodies. Flow cytometry was performed on FACS Aria II, and data were analyzed using FlowJo v10 (Tree Star) software.

Biotinylated pMHC-I multimers were conjugated with streptavidin-PE, and splenocytes were stained as described previously (18).

### **In Vitro Stimulation and Killer Assay**

Mice harboring memory OT-1 cells, primed with MCMV-SIINFEKL or RAE-1 $\gamma$ MCMV-SIINFEKL, were sacrificed and splenocytes isolated using a standard protocol.  $2 \times 10^6$  cells were then incubated for 6h with different concentrations of SIINFEKL peptide (JPT PeptideTechnologies GmbH) in RPMI 1640 (PAN-Biotech) supplemented with 10%FCS (PAN-Biotech), Brefeldin A (Invitrogen), Monensin (Invitrogen), and CD107 (Invitrogen) at 37°C.

For the *in vitro* killer assay, mice harboring memory OT-1 cells (CD45.1) were sacrificed and splenocytes isolated using a standard protocol. Splenocytes were pooled from 4-5 mice/group. CD8 T cells were purified by negative selection using magnetic beads (Miltenyi Biotec), and OT-1 (CD45.1) cells were stained with CD45.1 antibody and sorted using FACS Aria II (BD) using high-speed sorting into RPMI supplemented with 20% FCS. Sorted OT-1 (CD45.1) cells were co-incubated with E.G7-OVA (CD45.2) cells for 4h in 2:1, 1:1, and 0.5:1 effector to target ratios at 37°C. After co-incubations, target cells were identified as CD45.1 negative, and viability was determined using Fixable Viability Dye (eBioscience). OT-1 cytotoxicity was calculated using following formula:  $[(\% \text{ FVD}^+ \text{ CD45.1}^- \text{ cell-specific lysis} - \% \text{ FVD}^+ \text{ CD45.1}^- \text{ cell spontaneous lysis}) / (100 - \% \text{ FVD}^+ \text{ CD45.1}^- \text{ cell spontaneous lysis})] \times 100$  as described in (19).

### **Adoptive Transfer Experiments**

Naïve OT-1 cells were purified by negative selection using magnetic beads (Miltenyi Biotec).  $10^4$  OT-1 (CD45.1) cells were adoptively transferred into naïve C57BL/6J (CD45.2)

animals in 500  $\mu$ L DMEM i.v. For adoptive transfer experiments, mice harboring memory OT-1 cells primed with viral vectors were sacrificed, splenocytes were isolated using a standard protocol, and CD8 T cells were purified using magnetic beads (Miltenyi Biotec). Following magnetic separation, OT-1 (CD45.1) cells were stained with CD45.1 (Invitrogen) antibody and sorted using FACS Aria II (BD) using high-speed sorting into RPMI supplemented with 20% FCS. The purity and viability of sorted cells were checked immediately after sorting with PI staining and in all of the experiments exceeded 97%. Cells from 5-10 mice from each group were pooled, and  $3 \times 10^4$  cells were transferred in 500  $\mu$ L DMEM i.v. into mice harboring tumors.

### **RNAseq Sample Preparation and Sequencing**

Splenocytes were isolated from mice immunized with MCMV-SIINFEKL or RAE-1 $\gamma$ MCMV-SIINFEKL at day 36 post-immunization. CD8 T cells were purified using magnetic beads (Miltenyi Biotec). After magnetic beads separation, OT-1 (CD45.1) cells were stained with CD45.1 antibody (Invitrogen), high-speed sorted on FACS Aria II (BD) directly into the RLT lysis buffer (QIAGEN), and their total RNA isolated using RNeasy Micro Kit (QIAGEN), according to manufacturers' protocol. Agilent Bioanalyzer 2100 and Agilent RNA 6000 Nano Kit were used to estimate sample quality and determine the quantity of isolated RNA. Before library generation, RNA was subjected to DNase I digestion (Thermo Fisher Scientific) followed by RNeasy MinElute column clean up (Qiagen). RNAseq libraries were generated using the SMART-Seq v4 Ultra Low Input RNA Kit (Clontech Laboratories) following the manufacturer's recommendations. From cDNA, final libraries were generated utilizing the Nextera XT DNA Library Preparation Kit (Illumina). Concentrations of the final libraries were measured with a Qubit 2.0 Fluorometer (Thermo Fisher Scientific), and fragment lengths distribution was analyzed with the DNA High Sensitivity Chip on an Agilent 2100 Bioanalyzer (Agilent Technologies). All samples were normalized to 2nM and pooled at equimolar concentrations. The library pool was sequenced on the NextSeq500 (Illumina) in a single 1x84bp run, producing 22.5 M to 29.7 M reads per sample from a total of six mRNAseq libraries. Adapter sequences were hard-clipped from raw sequencing reads as part of the bcl2fastq pipeline (version 2.20.0.422). The overall quality of the trimmed sequences was assessed by FastQC v0.11.9. Where applicable, quality data from individual analyses were aggregated using MultiQC v1.9.

### **RNAseq Data Processing and Analysis**

RNAseq data processing and analysis were performed as described previously (20), with minor modifications specific to this study's experimental system. Briefly, following quality control using FastQC v0.11.9, sequencing libraries were searched for potentially contaminating sequences against an in-house database of common contaminants using FastQ Screen v0.14.0 (21) and Bowtie 2 v2.3.5.1 (22). Quality-checked

sequencing reads were then mapped to the mouse GRCm38.p6 (release M25) primary reference genome assembly (23) with STAR v2.7.6a (24–26), alignment files indexed using samtools v1.11 (27), and reads mapping to individual genes counted using featureCounts (28). Obtained uniquely mapped read counts were used for differential expression analysis, which was performed with the DESeq2 package (29), applying  $p_{\text{adj}} < 0.05$  as a cutoff for statistical significance. Gene ontology overrepresentation analysis was performed using the clusterProfiler package v3.14.1 (30), and heatmaps were generated using R package pheatmap v.1.0.12 (<https://CRAN.R-project.org/package=pheatmap>).

## Statistical Analysis

Unpaired t-test, ANOVA (followed by LSD post test), and log-rank Mantel-Coy test were performed using Prism software (GraphPad Software Inc., La Jolla, CA).  $P < 0.05$  was considered statistically significant.

## RESULTS

### RAE-1 $\gamma$ MCMV Confers Robust Long-Term Protection Against Subcutaneous Tumor Challenges


To expand on our previous work (6) and investigate the robustness of protection conferred to mice immunized with RAE-1 $\gamma$ MCMV against tumor challenge, we utilized viral vectors expressing H2Kb restricted SIINFEKL epitope (6, 15). C57BL/6/J mice were immunized with MCMV-SIINFEKL, RAE-1 $\gamma$ MCMV-SIINFEKL, or left unimmunized. Two months following the immunization, mice were challenged with E.G7-OVA lymphoma expressing SIINFEKL epitope, and tumor appearance and growth were followed over time (**Figure 1A**). Unimmunized mice rapidly developed large tumors while MCMV-SIINFEKL immunized mice developed smaller tumors that subsequently retracted (**Figure 1B**). Conversely, all of RAE-1 $\gamma$ MCMV-SIINFEKL immunized mice failed to develop observable tumors during the initial three weeks after tumor inoculation, and the overall percentage of mice that developed tumors was much smaller than MCMV-SIINFEKL immunized animals (**Figure 1C**). Furthermore, immunization with either of these two vectors substantially increased the overall survival of mice after the tumor challenge. Although the survival rate was higher in mice immunized with RAE-1 $\gamma$ MCMV-SIINFEKL than in MCMV-SIINFEKL immunized mice (80% vs. 64% survival), the difference was not statistically significant (**Figure 1D**). Next, two months after primary challenge, survivors of E.G7-OVA tumor were inoculated with a different, more malignant neoplasm expressing the same SIINFEKL epitope, B16-OVA melanoma (**Figure 1E**). Again, RAE-1 $\gamma$ MCMV-SIINFEKL immunization led to an increase in the survival rate as 91% of mice survived the challenge in this group compared to 75% in the MCMV-SIINFEKL immunized group (**Figure 1F**). To confirm that the protection against secondary tumor challenge is

mediated *via* CD8 T cells, half of the mice in each group were depleted of this lymphocyte population starting one day prior to the B16-OVA challenge. Mice lacking cytotoxic T cells quickly succumbed to tumor challenge, proving that this population mediates the protection.

We went on to investigate the therapeutic potential of the RAE-1 $\gamma$ MCMV-SIINFEKL vector in the E.G7-OVA challenge. Mice were inoculated with E.G7-OVA subcutaneously and 6 days later immunized with MCMV-SIINFEKL or RAE-1 $\gamma$ MCMV-SIINFEKL, whereas one group of mice was left unimmunized (**Figure 1G**). RAE-1 $\gamma$ MCMV-SIINFEKL vaccination was superior to MCMV-SIINFEKL vaccination in tumor size reduction (**Figure 1H**) and substantially increased the survival of mice inoculated with E.G7-OVA lymphoma cells (**Figure 1I**). Overall, the MCMV vector expressing RAE-1 $\gamma$  in place of its viral inhibitor proved more efficient than the wild-type MCMV vector in protection against subcutaneous tumor challenge in both prophylactic and therapeutic settings.

### Memory CD8 T Cells Primed With RAE-1 $\gamma$ MCMV Exhibit a Distinct Transcriptional Profile


We have previously shown that RAE1 $\gamma$ MCMV-SIINFEKL has enhanced priming capacity compared to the wild-type MCMV vector (6, 7). However, differences in phenotype and function of memory populations of SIINFEKL specific CD8 T cells induced with these viral vectors remained poorly characterized. To screen for distinct characteristics in memory populations induced with indicated vectors, we compared their transcriptional profiles at the memory timepoint.  $10^4$  congenic OT-1 T cells (expressing H-2Kb-SIINFEKL restricted TCR) were transferred to naïve animals that were subsequently vaccinated with MCMV-SIINFEKL or RAE-1 $\gamma$ MCMV-SIINFEKL (**Figure 2A**). The transcriptional profile of OT-1 cells was determined on day 36 post-vaccination. Overall, 249 genes were differentially expressed between OT-1 cells primed with MCMV-SIINFEKL and RAE-1 $\gamma$ MCMV-SIINFEKL (**Table S1**). Gene ontology overrepresentation analysis revealed that differentially expressed genes between these two groups participate in biological processes related to proliferation, cellular division, and cellular activation involved in immune response (**Figure 2B**). Interestingly, both *Sell* (CD62L) and *Ccr7*, coding for prototypical markers of central memory phenotype (31), as well as the antiapoptotic molecule *Bcl2*, were more strongly transcribed in the MCMV-SIINFEKL immunized group. Simultaneously, RAE-1 $\gamma$ MCMV-SIINFEKL primed cells showed higher expression of transcripts associated with an effector-like phenotype, such as *Cx3Cr1* (32), *Gzma*, *Gzmb*, *Adam8*, *Cd244a*, *Lgals3*, and *Lgals1* (33, 34) (**Figure 2C**). These differences prompted us to analyze other genes associated with central memory and effector-like phenotype below the chosen significance threshold. In the MCMV-SIINFEKL group, we observed a clear trend in the expression of other transcripts associated with Tcm such as *Tcf7* (35), *Id3*, *Eomes*, *Il7r* (36), and *Cd27* (12) which were also elevated. At the same time, effector marker *Klrg1* (36) was more highly



**FIGURE 1** | RAE-1 $\gamma$ MCMV-SIINFEKL confers robust long-term protection against subcutaneous tumor challenges. **(A)** Mice were immunized with either MCMV-SIINFEKL, RAE-1 $\gamma$ MCMV-SIINFEKL, or left unimmunized (n=10-20). 2 months after immunization, mice were inoculated with E.G7-OVA tumor subcutaneously. **(B)** Tumor growth was followed over time. **(C)** Percent of mice that developed tumors (>15 mm<sup>2</sup>). **(D)** Overall survival after E.G7-OVA challenge. **(E)** Mice that survived the initial E.G7-OVA challenge were further challenged with B16-OVA subcutaneously. Half of the survivors were depleted for CD8 T cells prior to the secondary challenge. **(F)** Overall survival of mice after secondary challenge. **(G)** Mice were inoculated with E.G7-OVA subcutaneously. 6 days later, mice were immunized with indicated vectors or left unimmunized (n=10). **(H)** Tumor growth and **(I)** overall survival were followed over time. Prophylactic data are from a single experiment representative of two independent experiments (**B**, **C**). Survival data are pooled from two independent experiments (**D**, **F**). Therapeutic data are from a single experiment representative of two independent experiments (**H**), and survival data are pooled from two independent experiments (**I**). Data are represented as mean  $\pm$  SEM (**B**, **H**) and statistical significance is expressed as \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001. Statistical significance was tested using one-way ANOVA followed by LSD post test (**B**, **H**) or log-rank Mantel-Cox test for Kaplan-Meier curves (**C**, **D**, **F**, **I**).

transcribed in RAE-1 $\gamma$ MCMV-SIINFEKL immunized mice (**Figure 2D**). Furthermore, many genes linked with progression through the cell cycle were more highly transcribed in cells primed with RAE-1 $\gamma$ MCMV-SIINFEKL,

suggesting their higher proliferation rate (**Figure 2E**). Together, RNAseq data strongly associated OT-1 cells primed with RAE-1 $\gamma$ MCMV-SIINFEKL and MCMV-SIINFEKL with effector-like and central memory phenotype, respectively.




**FIGURE 2 |** Memory CD8 T cells primed with RAE-1 $\gamma$ MCMV exhibit a distinct transcriptional profile. **(A)**  $10^4$  naive OT-1 cells were transferred to C57BL/6J mice one day prior to immunization with MCMV-SIINFEKL or RAE-1 $\gamma$ MCMV-SIINFEKL (n=3). **(B)** Gene ontology overrepresentation analysis (GO-ORA) of identified differentially expressed genes. Bar chart showing selected, statistically significant GO terms in the Biological process category, ranked by adjusted p-values. **(C)** Heat map showing the expression of indicated genes. **(D)** Transcription of indicated genes below chosen significance threshold. **(E)** Heat map showing the expression of genes belonging to the GO term “Mitotic cell cycle phase transition”. Data are from a single experiment. Genes and GO terms with padj<0.05 were considered statistically significant.

### RAE-1 $\gamma$ MCMV-SIINFEKL Has Superior Priming Capacity and Generates Phenotypically Distinct Memory CD8 T Cells

We validated gene expression data and analyzed the kinetics and phenotype of OT-1 cells primed with viral vectors using flow cytometry. To that aim,  $10^4$  congenic OT-1 T cells were transferred to naïve animals that were subsequently vaccinated with MCMV-SIINFEKL or RAE-1 $\gamma$ MCMV-SIINFEKL (Figure 3A). The frequency of OT-1 T cells was followed over time. The initial expansion of OT-1 cells was substantially increased in RAE-1 $\gamma$ MCMV-SIINFEKL immunized mice compared to MCMV-SIINFEKL immunized animals, and OT-1 T cells were maintained at significantly higher levels in the RAE1 $\gamma$ MCMV-SIINFEKL group compared to MCMV-

SIINFEKL group (Figures 3B, C). Importantly, OT-1 cells in RAE1 $\gamma$ MCMV-SIINFEKL showed signs of memory inflation, as the frequency of these cells increased in later time points. Confirming our RNAseq data, we observed major phenotypical differences between OT-1 cells primed with different vectors. Notably, the frequency of cells expressing the TCF1 transcription factor was significantly lower in the RAE1 $\gamma$ MCMV-SIINFEKL immunized group than in the MCMV-SIINFEKL immunized mice (Figure 3D, left). RAE-1 $\gamma$ MCMV-SIINFEKL primed OT-1 cells showed a higher frequency of KLRG1 $^+$  cells in accordance with RNAseq data (Figure 3D, right). Interestingly, these differences were not present at initial time points during acute CD8 T cell response but manifested themselves at memory time points, around day 30. A detailed phenotypical analysis of OT-1 cells at day 37 corroborated our RNAseq findings, as RAE-



**FIGURE 3** | RAE-1 $\gamma$ MCMV-SIINFEKL has superior priming capacity and generates phenotypically distinct memory CD8 T cells. **(A)** 10<sup>4</sup> naive OT-1 cells were transferred to C57BL/6J mice one day prior to immunization with MCMV-SIINFEKL or RAE-1 $\gamma$ MCMV-SIINFEKL (n=4-5). **(B)** OT-1 frequency (blood) at indicated time points post-immunization. **(C)** Absolute numbers of OT-1 cells at day 7 post-immunization in the spleen. **(D)** Kinetics of TCF1<sup>+</sup> and KLRG1<sup>+</sup> populations were followed in blood over time. **(E)** The phenotype of memory OT-1 cells primed with indicated viruses at day 37 post-immunization shown as the percentage of TCF1<sup>+</sup>, CD62L<sup>+</sup>, CD27<sup>+</sup>, CD127<sup>+</sup> OT-1 cells, and MFI of Eomes on OT-1 cells. **(F)** Expression of indicated molecules on TCF1<sup>+</sup> and TCF1<sup>-</sup> cells. Data are from a single experiment representative of two independent experiments. Data are represented as mean  $\pm$  SEM and statistical significance as \*p < 0.05, \*\*p < 0.01, \*\*\*\*p < 0.0001. Statistical significance was determined using unpaired Student t-test.



1 $\gamma$ MCMV-SIINFEKL primed OT-1 cells expressed lower levels of CD62L, CD127, and CD27 as well as TCF1 and Eomes transcription factors (**Figure 3E**). To confirm that TCF1 expression successfully delineates two distinct populations with different phenotypical features, we compared the expression of several molecules on TCF1<sup>+</sup> and TCF1<sup>-</sup> cells. CD127, CD27, Eomes, and CD62L expression were all significantly elevated in TCF1<sup>+</sup> cells, while KLRG1 and Tbet showed a significant increase in TCF1<sup>-</sup> population (**Figure 3F**). These data convincingly demonstrate that RAE-1 $\gamma$ MCMV-SIINFEKL induces memory CD8 T cells with distinct, effector-like phenotypical features that grossly differ from memory CD8 T cells primed with the vector lacking RAE-1 $\gamma$  expression.

### CD8 T Cells Primed With RAE-1 $\gamma$ MCMV Show Lower Cytokine-Producing Capabilities Than Cells Primed With the Virus Lacking RAE-1 $\gamma$ but Similar Cytotoxic Potential

Distinct phenotypical features are associated with different functionality of memory CD8 T cells (31, 36). To compare the cytokine-producing capabilities of cells primed with RAE-1 $\gamma$ MCMV-SIINFEKL or MCMV-SIINFEKL on a per cell basis, OT-1 cells were transferred to naïve animals that were immunized with indicated viruses the following day. On day 50, mice were sacrificed, splenocytes were isolated and stimulated with different SIINFEKL peptide concentrations (**Figure 4A**). OT-1 cells primed with the virus lacking RAE-1 $\gamma$  showed higher cytokine-producing capabilities as measured by frequency of IFN $\gamma$ , TNF $\alpha$  and IL-2 positive cells (**Figures 4B, C**). Furthermore, MCMV-SIINFEKL induced memory OT-1 cells also showed enhanced degranulation ability as measured by mobilization of LAMP-1 (CD107a) molecule (**Figure 4D**). Despite the difference in CD107a mobilization, RAE-1 $\gamma$ MCMV-SIINFEKL primed OT-1 cells showed equal or higher Granzyme B content (**Figure 4E**), suggesting the equal or higher cytotoxic potential of these cells when compared to OT-1 cells primed with wild-type virus. We sorted OT-1 cells from immunized mice at memory time point to compare the cytotoxicity of cells primed with these two vectors and incubated them in different ratios with E.G7-OVA cells. OT-1 cells primed with RAE-1 $\gamma$ MCMV-SIINFEKL showed enhanced but not significantly different cytotoxic potential against tumor cells (**Figure 4F**), confirming previous studies that revealed that degranulation and cytotoxic potential do not necessarily correlate (37). KLRG1<sup>+</sup> population was enriched in OT-1 cells primed with RAE-1 $\gamma$  expressing vector, and we wondered whether there was any difference in the functional capacity of this population compared to cells lacking KLRG1 expression. KLRG1<sup>+</sup> cells had a lower frequency of IFN $\gamma$  and IL-2 producing cells, showed lower degranulation capacity, but simultaneously had higher per cell content of cytotoxic Granzyme B molecule (**Figure 4G**). Therefore, RAE-1 $\gamma$ MCMV-SIINFEKL primed OT-1 cells at the memory time point showed lower cytokine-producing capabilities and a lower percentage of cells mobilizing CD107a during *in vitro* stimulation. On the other


hand, these cells had higher per cell Granzyme B content and similar or slightly elevated cytotoxic potential against tumor cells expressing their cognate antigen.

### Adoptively Transferred CD8 T Cells Primed With RAE-1 $\gamma$ MCMV Vector Show Protective Potential Similar to Cells Primed With the MCMV Lacking RAE-1 $\gamma$

Prophylactic and therapeutic vaccination protocol established that immunization with RAE-1 $\gamma$ MCMV-SIINFEKL confers greater protection against tumor challenge than immunization with a vector lacking RAE-1 $\gamma$ . To assess the protective capabilities of OT-1 cells generated with indicated vectors when an equal number of cells are transferred into naïve hosts, we performed an adoptive transfer experiment. OT-1 (CD45.1) cells were primed with indicated viruses, and at a memory time point, equal numbers of OT-1 cells were sorted and transferred into mice that were inoculated with E.G7-OVA tumors 5 days prior to transfer (**Figure 5A**). Both populations of transferred OT-1 cells were successful in tumor control (**Figure 5B**), and the survival rate was similar in both groups, 65% and 68% for MCMV-SIINFEKL and RAE-1 $\gamma$ MCMV-SIINFEKL primed OT-1 cells, respectively (**Figure 5C**). Several studies associated TCF1<sup>+</sup> memory cells with increased proliferative capabilities (35, 38, 39), and accordingly, the initial response was somewhat augmented in OT-1 cells primed with the wild-type MCMV vector. However, by day 15 post-transfer, the difference was lost (**Figure 5D**). In line with previous findings (40), OT-1 cells in both groups became TCF1<sup>low</sup> during recall response, but RAE-1 $\gamma$ MCMV primed cells still maintained elevated expression of KLRG1 (**Figure 5E**). We also analyzed the expression of CD8 T cell exhaustion markers PD-1 and Tim-3 on OT-1 cells, as well as Tox, a transcription factor crucially associated with T cell exhaustion (41). We found no difference in the expression of these molecules, suggesting the absence of CD8 T cell exhaustion in both groups (**Figure 5F**). Overall, OT-1 cells primed with both vectors showed comparable protective capabilities against subcutaneous tumor challenge after adoptive transfer into naïve hosts.

## DISCUSSION


In our previous work, we have demonstrated the potential of MCMV expressing NKG2D ligand RAE-1 $\gamma$  as a viral vaccine vector in the generation of CD8 T cell response to an inserted foreign epitope in the context of bacterial (6) and tumor challenge (7). We expanded our findings regarding the robust, long-term protection conferred by RAE-1 $\gamma$ MCMV immunization against tumor challenge. First, we confirmed that this vector can induce substantially higher numbers of CD8 T cells specific for inserted foreign epitope than the vector lacking NKG2D ligand expression. Next, the transcriptomic analysis revealed ~250 differentially expressed genes between OT-1 cells derived from mice immunized with RAE-1 $\gamma$ MCMV and WT MCMV vectors and uncovered



**FIGURE 4** | CD8 T cells primed with RAE-1 $\gamma$ MCMV show lower cytokine-producing capabilities than cells primed with the virus lacking RAE-1 $\gamma$  but similar cytotoxic potential. **(A)** Naive OT-1 (CD45.1) cells were transferred to CD57BL/6J mice (CD45.2). One day after the transfer, mice were immunized with indicated viruses (n=5-6). On day 50, mice were sacrificed, and splenocytes were stimulated with different concentrations of SIINFEKL peptide. Production of IFN- $\gamma$  and TNF- $\alpha$  **(B)**, IL-2 **(C)**, CD107a **(D)**, Granzyme B **(E)** was analyzed using flow cytometry. **(F)** Memory time point OT-1 cells were incubated with E.G7-OVA cells in indicated effector:target ratios. **(G)** Percentage or MFI of indicated molecules in KLRG1<sup>+</sup> and KLRG1<sup>-</sup> cells. Data are from a single experiment representative of two independent experiments. Data is represented as mean  $\pm$  SEM and statistical significance \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001. Statistical significance was determined using unpaired Student t-test.

that genes associated with effector-like phenotype and cellular proliferation are more strongly expressed in RAE-1 $\gamma$  MCMV primed cells. Using flow cytometry, we validated these findings on protein levels for several genes. Remarkably, CD8 T

cells induced by RAE-1 $\gamma$  expressing MCMV vector were predominantly TCF1 negative and showed effector-like phenotype (KLRG1<sup>+</sup> CD127<sup>-</sup> CD27<sup>-</sup> CD62L<sup>-</sup>). Finally, we showed that this phenotypical difference is associated with



**FIGURE 5** | Adoptively transferred CD8 T cells primed with RAE-1 $\gamma$ MCMV vector show protective potential similar to cells primed with the MCMV lacking RAE-1 $\gamma$ . **(A)** Naive OT-1 cells were transferred into C57BL/6 mice (n=8-10) one day prior to immunization with indicated viruses. On day 44 after immunization,  $3 \times 10^4$  memory OT-1 cells were sorted and transferred to mice (n=11) that were inoculated with E.G7-OVA tumors 5 days prior to OT-1 transfer. Tumor growth **(B)** and overall survival **(C)** were followed over time. **(D)** The frequency of OT-1 cells was determined in blood at indicated time points. **(E, F)** The phenotype of OT-1 cells was analyzed on day 15 following adoptive transfer in blood. Data are from a single experiment representative of two independent experiments **(B, D-F)**. Survival data are pooled from two independent experiments **(C)**. Data are represented as mean  $\pm$  SEM and statistical significance \*p < 0.05; \*\*p < 0.01. Statistical significance was determined using one-way ANOVA followed by LSD post test **(B)**, log-rank Mantel-Cox test **(C)**, or unpaired Student t-test **(D-F)**.

distinct functional capabilities of cells primed with indicated vectors in a series of functional assays. RAE-1 $\gamma$ MCMV primed OT-1 cells produced lower amounts of IFN $\gamma$ , TNF $\alpha$  and IL-2, showed decreased degranulation potential, while simultaneously exhibiting similar cytotoxicity against tumor cells expressing their cognate antigen. However, when we transferred equal numbers of memory OT-1 cells primed with MCMV-SIINFEKL or RAE-1 $\gamma$ MCMV-SIINFEKL into mice harboring subcutaneous tumors, OT-1 cells induced with both vectors were comparably successful in rejecting established tumors.

Memory CD8 T cells are traditionally divided by CD62L and/or CCR7 expression on central memory (Tcm) and effector memory (Tem) populations. These phenotypical properties were thought to entail functional distinction, as original reports identified the CCR7<sup>-</sup> CD62L<sup>-</sup> effector memory

population as superior in cytokine production, whereas the central memory population was shown to exhibit enhanced proliferative capabilities (31). Further reports quickly led to a more complicated picture of functional division. For instance, Wherry et al. showed no substantial difference in cytokine-producing abilities (except IL-2 production) or cytotoxicity on per cell basis between Tcm and Tem in LCMV infection. At the same time, several other studies in different models obtained contrasting results, as Tem cells proved more protective and demonstrated higher cytotoxic capabilities (42, 43). In a recent study (11), the Tem population was further subdivided into effector-like CD127<sup>low</sup> CD62L<sup>low</sup> (terminal-Tem) and CD127<sup>high</sup> CD62L<sup>low</sup> (Tem). The effector-like terminal-Tem population (notably also expressing high levels of KLRG1) conferred the greatest protection against *Listeria monocytogenes* infection but

minimal protection against tumor challenge, indicating that protective capacity is highly dependent on the disease and therapeutic context. Our transcriptomic analysis revealed several effector genes, such as *Cx3Cr1*, *Gzma*, *Gzmb*, *Adam8*, *Cd244a*, and *Lgals3*, were upregulated in CD8 T cells primed with RAE-1 $\gamma$ MCMV, suggesting their greater cytotoxic capabilities. *Cx3cr1* is a particularly interesting gene, as one study proposed memory CD8 T cell subset classification based on the expression of this marker (32). In that study, CX3CR1<sup>high</sup> cells were CD27<sup>-</sup>, CD127<sup>-</sup> and KLRG1<sup>+</sup> and produced smaller amounts of cytokines but displayed greater cytotoxic potential, therefore closely corresponding to OT-1 cells primed with RAE-1 $\gamma$ MCMV. Interestingly, despite somewhat enhanced cytotoxicity, we observed decreased degranulation of RAE-1 $\gamma$ MCMV primed OT-1 cells as measured by LAMP1 (CD107a) mobilization. Previous reports also demonstrated decoupling of degranulation and cytotoxicity in memory CD8 T cells specific for viral antigens, confirming that our observation is not an isolated finding (37). Furthermore, both RNAseq and flow cytometry data demonstrated elevated levels of Granzyme B in RAE-1 $\gamma$ MCMV primed OT-1 cells indicating granule content as a better predictor of cytotoxicity than degranulation per se. This is also illustrated by the fact that KLRG1<sup>+</sup> cells consistently showed lower levels of LAMP1 mobilization and substantially higher per cell content of Granzyme B.

Two aspects of CD8 T cell response are crucial for cellular immunity induced by a vaccine to be successful: cell numbers and their functionality. RAE-1 $\gamma$ MCMV-SIINFEKL induced much higher numbers of OT-1 cells by day 7, which remained elevated throughout the experiment and showed distinct phenotypical and functional features. MCMV-SIINFEKL primed OT-1 cells, enriched in the TCF1<sup>+</sup> population, appeared to have slightly augmented recall response and cytokine-producing capabilities. However, when we transferred equal numbers of OT-1 cells primed with RAE-1 $\gamma$  expressing vector or wild-type viral vector, both of these populations successfully rejected established tumors. Therefore, superior cytokine production and recall response of MCMV-SIINFEKL induced OT-1 cells was, perhaps, compensated by slightly elevated cytotoxicity or different tumor-infiltrating potential of RAE-1 $\gamma$ MCMV primed OT-1 cells, leading to a similar anti-tumor response *in vivo* by adoptively transferred cells. These results indicate that the enhanced anti-tumor potential demonstrated in **Figure 1**, might depend on the immunological milieu provided by chronic/latent infection by MCMV vector expressing RAE-1 $\gamma$  and the superior numbers of SIINFEKL specific CD8 T cells.

The mechanistic explanation for superior priming and maintenance of CD8 T cells in RAE-1 $\gamma$ MCMV immunized mice remains unanswered. Increased frequency of CD8 T cells might be due to the costimulatory nature of NKG2D signaling on these cells. However, several studies have shown no substantial alterations in frequency or absolute numbers of CD8 T cells that lacked NKG2D signaling during priming (44–46), and we observed no diminishment in the frequency of CD8 T cells in RAE-1 $\gamma$ MCMV immunized NKG2D deficient mice (6), nor in conditional knock-out mice in which NKG2D receptor is

specifically lacking in T lymphocytes (**Figure S1**). It is also possible that RAE-1 $\gamma$  mediates its function through a yet unknown interaction partner, which would explain the persistence of this phenotype even in *Klrk1*<sup>-/-</sup> animals. On the other hand, in RAE-1 $\gamma$  expressing vector, the gene is inserted in place of its viral inhibitor *m152*, which has several functions, including the retention of MHC-I molecules in ERGIC-cis Golgi compartment (47). This suggests that CD8 T cells primed with RAE-1 $\gamma$ MCMV have stronger TCR signalling, which is known to directly correlate with the magnitude of T cell response (48, 49) and thus provides a feasible hypothesis for superior initial expansion of epitope specific CD8 T cells in RAE-1 $\gamma$ MCMV immunized mice. However, this would only apply to CD8 T cells primed *via* direct presentation by infected dendritic cells and not during cross-presentation which was shown to have a far more important role in T cell response to MCMV epitopes (50, 51). Finally, m152 protein delays STING protein trafficking to Golgi compartment and, hence abrogates type I IFN response (52). Type I interferons are potent modulators of T cell proliferation and differentiation (53) and this increased interferon signalling could have an impact on T cell expansion in mice immunized with RAE-1 $\gamma$  expressing vector. Our preliminary results suggest that this is not the case, as we failed to observe any difference in T cell response to RAE-1 $\gamma$ MCMV-SIINFEKL in STING deficient animals compared to control animals (data not shown).

Tcm phenotype is crucially connected with TCF1 expression (35, 38). Major phenotypical differences between OT-1 cells primed with RAE-1 $\gamma$ MCMV and wild type vector regarding the expression of this transcription factor became apparent only at memory time points, around day 30. Therefore, either TCF1<sup>+</sup> cells in the RAE-1 $\gamma$ MCMV group died off or were converted to TCF1<sup>-</sup> population. This conversion might be the result of an antigen encounter. Welten et al. (54) showed that TCF1<sup>+</sup> cells give rise to TCF1<sup>-</sup> only in the presence of latent antigenic load. Although RAE-1 $\gamma$ MCMV establishes a lower level of latent viral load (5), immunization with this vector might lead to more frequent reactivation events or higher antigen expression on latently infected cells and higher T cell stimulation. This would not only explain the difference in phenotype between T cells primed with indicated vectors, but also signs of memory inflation in RAE-1 $\gamma$ MCMV immunized mice and the fact that some of the most abundantly transcribed genes in this group were associated with cellular proliferation and TCR stimulation (*Lgals3* and *Zbtb32*). Another explanation for the phenotypical and functional differences might be due to different priming conditions imprinting the long-term fate of these cells on the epigenetic level. Pace et al. identified histone methyltransferases Suv39h1 as a potent epigenetic silencer of genes related to stemness/memory potential such as *Il7r*, *Eomes*, and *Ccr7* (33). Epigenetic mechanisms play a crucial role in poising the cells towards particular phenotype and functionality (55), and it would be interesting to investigate whether RAE-1 $\gamma$ MCMV confers distinct epigenetic states to cells primed with this vector.

Overall, our study confirms great potential of highly attenuated CMV viral vectors expressing NKG2D ligand in

prophylactic and therapeutic vaccine settings. The translational possibilities of CMV vectors expressing ligands for activating immune receptors are further supported by potent cellular immune response induced by human CMV vector expressing NKG2D ligand ULBP2 (56). More fundamentally, our study also indicates that small genetical changes of viral vectors can lead to gross differences in CD8 T cell expansion, phenotype, and function.

## DATA AVAILABILITY STATEMENT

The RNAseq data has been uploaded to the European nucleotide archive, with accession number: PRJEB44407.

## ETHICS STATEMENT

The animal study was reviewed and approved by Ethics Committee of the Veterinary Department of the Ministry of Agriculture.

## AUTHOR CONTRIBUTIONS

MŠ, IB, AK, and SJ designed the study. MŠ, MC, JM, CR, VL, and LH performed the experiments. MŠ and BL analyzed the data. DI performed RNA sequencing. DB provided reagents. MŠ wrote

the manuscript. SJ, AK, IB, and BL critically read and revised the manuscript. SJ and AK supervised the study. All authors contributed to the article and approved the submitted version.

## FUNDING

This work has been supported by the grant “Strengthening the capacity of CerVirVac for research in virus immunology and vaccinology”, KK.01.1.1.01.0006, awarded to the Scientific Centre of Excellence for Virus Immunology and Vaccines and co-financed by the European Regional Development Fund (SJ), by the Croatian-Swiss Research Program of the Croatian Science Foundation and the Swiss National Science Foundation with funds obtained from the Swiss-Croatian Cooperation Programme (AK) and by the Croatian Science Foundation under the project IP-2018-01-9086 (AK).

## ACKNOWLEDGMENTS

We thank A. Miše, E. Ražić, D. Rumora, M. Samsa, S. Slavić-Stupac, N. Vragović and M. Zamuda for excellent technical support.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2021.681380/full#supplementary-material>

## REFERENCES

- Chen DS, Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. *Immunity* (2013) 39(1):1–10. doi: 10.1016/j.immuni.2013.07.012
- Klenerman P, Oxenius A. T Cell Responses to Cytomegalovirus. *Nat Rev Immunol* (2016) 16(6):367–77. doi: 10.1038/nri.2016.38
- Berry R, Watson GM, Jonjic S, Degli-Esposti MA, Rossjohn J. Modulation of Innate and Adaptive Immunity by Cytomegaloviruses. *Nat Rev Immunol* (2020) Feb20(2):113–27. doi: 10.1038/s41577-019-0225-5
- Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of Ligands for the NKG2D Activating Receptor. *Annu Rev Immunol* (2013) 31:413–41. doi: 10.1146/annurev-immunol-032712-095951
- Slavuljica I, Busche A, Babić M, Mitrović M, Gašparović I, Cekinović Đ, et al. Recombinant Mouse Cytomegalovirus Expressing a Ligand for the NKG2D Receptor is Attenuated and has Improved Vaccine Properties. *J Clin Invest* (2010) 120(12):4532–45. doi: 10.1172/JCI43961
- Tršan T, Busche A, Abram M, Wensveen FM, Lemmermann NA, Arapovic M, et al. Superior Induction and Maintenance of Protective CD8 T Cells in Mice Infected With Mouse Cytomegalovirus Vector Expressing RAE-1. *Proc Natl Acad Sci* (2013) 110(41):16550–5. doi: 10.1073/pnas.1310215110
- Tršan T, Vuković K, Filipović P, Brizić AL, Lemmermann NAW, Schober K, et al. Cytomegalovirus Vector Expressing RAE-1 $\gamma$  Induces Enhanced Anti-Tumor Capacity of Murine CD8+ T Cells. *Eur J Immunol* (2017) 47(8):1354–67. doi: 10.1002/eji.201746964
- Herdler-Brandstetter D, Ishigame H, Shinnakasu R, Plajer V, Stecher C, Zhao J, et al. KLRG1+ Effector CD8+ T Cells Lose KLRG1, Differentiate Into All Memory T Cell Lineages, and Convey Enhanced Protective Immunity. *Immunity* (2018) 48(4):716–29.e8. doi: 10.1016/j.immuni.2018.03.015
- Kaech SM, Cui W. Transcriptional Control of Effector and Memory CD8+ T Cell Differentiation. *Nat Rev Immunol* (2012) 12(11):749–61. doi: 10.1038/nri3307
- Graef P, Buchholz VR, Stemberger C, Flossdorf M, Henkel L, Schiemann M, et al. Serial Transfer of Single-Cell-Derived Immunocompetence Reveals Stemness of CD8+ Central Memory T Cells. *Immunity* (2014) 41(1):116–26. doi: 10.1016/j.immuni.2014.05.018
- Milner JJ, Nguyen H, Omilusik K, Reina-Campos M, Tsai M, Toma C, et al. Delineation of a Molecularly Distinct Terminally Differentiated Memory CD8 T Cell Population. *Proc Natl Acad Sci USA* (2020) 117(41):25667–78. doi: 10.1073/pnas.2008571117
- Olson JA, McDonald-Hyman C, Jameson SC, Hamilton SE. Effector-Like CD8+ T Cells in the Memory Population Mediate Potent Protective Immunity. *Immunity* (2013) 38(6):1250–60. doi: 10.1016/j.immuni.2013.05.009
- Jameson SC, Masopust D. Understanding Subset Diversity in T Cell Memory. *Immunity* (2018) 48(2):214–26. doi: 10.1016/j.immuni.2018.02.010
- Lenartić M, Jelenčić V, Zafirova B, Ožanić M, Marečić V, Jurković S, et al. NKG2D Promotes B1a Cell Development and Protection Against Bacterial Infection. *J Immunol* (2017) 198(4):1531–42. doi: 10.4049/jimmunol.1600461
- Lemmermann NAW, Gergely K, Böhm V, Deegen P, Däubner T, Reddehase MJ. Immune Evasion Proteins of Murine Cytomegalovirus Preferentially Affect Cell Surface Display of Recently Generated Peptide Presentation Complexes. *J Virol* (2010) 84(3):1221–36. doi: 10.1128/JVI.02087-09
- Brizić I, Lisnić B, Brune W, Hengel H, Jonjic S. Cytomegalovirus Infection: Mouse Model. *Curr Protoc Immunol* (2018) 122(1):e51. doi: 10.1002/cpim.51
- Cossarizza A, Chang H-D, Radbruch A, Acas A, Adam D, Adam-Klages S, et al. Guidelines for the Use of Flow Cytometry and Cell Sorting in Immunological Studies (Second Edition). *Eur J Immunol* (2019) 49(10):1457–973. doi: 10.1002/eji.201970107

18. Schober K, Voit F, Grassmann S, Müller TR, Eggert J, Jarosch S, et al. Reverse TCR Repertoire Evolution Toward Dominant Low-Affinity Clones During Chronic CMV Infection. *Nat Immunol* (2020) 21(4):434–41. doi: 10.1038/s41590-020-0628-2
19. Babić M, Pyzik M, Zafirova B, Mitrović M, Butorac V, Lanier LL, et al. Cytomegalovirus Immuno-evasin Reveals the Physiological Role of “Missing Self” Recognition in Natural Killer Cell Dependent Virus Control In Vivo. *J Exp Med* (2010) 207(12):2663–73. doi: 10.1084/jem.20100921
20. Kveštak D, Jurančić Lisnić V, Lisnić B, Tomac J, Golemac M, Brzić I, et al. NK/ILC1 Cells Mediate Neuroinflammation and Brain Pathology Following Congenital CMV Infection. *J Exp Med* (2021) 218(5):e20201503. doi: 10.1084/jem.20201503
21. Wingett SW, Andrews S. Fastq Screen: A Tool for Multi-Genome Mapping and Quality Control [Version 1; Referees: 3 Approved, 1 Approved With Reservations]. *F1000Research* (2018) 7(0):1–13. doi: 10.12688/f1000research.15931.2
22. Langmead B, Salzberg SL. Fast Gapped-Read Alignment With Bowtie 2. *Nat Methods* (2012) 9(4):357–9. doi: 10.1038/nmeth.1923
23. Frankish A, Diekhans M, Ferreira A-M, Johnson R, Jungreis I, Loveland J, et al. GENCODE Reference Annotation for the Human and Mouse Genomes. *Nucleic Acids Res* (2019) 47(D1):D766–73. doi: 10.1093/nar/gky955
24. Dobin A, Gingeras TR. Optimizing RNA-Seq Mapping With STAR. *Methods Mol Biol* (2016) 1415:245–62. doi: 10.1007/978-1-4939-3572-7\_13
25. Dobin A, Gingeras TR. Mapping RNA-seq Reads With STAR. *Curr Protoc Bioinformatics* (2015) 51:11.14.1–11.14.19. doi: 10.1002/0471250953.bi1114s51
26. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: Ultrafast Universal RNA-seq Aligner. *Bioinformatics* (2013) 29(1):15–21. doi: 10.1093/bioinformatics/bts635
27. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map Format and SAMtools. *Bioinformatics* (2009) 25(16):2078–9. doi: 10.1093/bioinformatics/btp352
28. Liao Y, Smyth GK, Shi W. featureCounts: An Efficient General Purpose Program for Assigning Sequence Reads to Genomic Features. *Bioinformatics* (2014) 30(7):923–30. doi: 10.1093/bioinformatics/btt656
29. Love MI, Huber W, Anders S. Moderated Estimation of Fold Change and Dispersion for RNA-seq Data With DESeq2. *Genome Biol* (2014) 15(12):550. doi: 10.1186/s13059-014-0550-8
30. Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: An R Package for Comparing Biological Themes Among Gene Clusters. *OMICS* (2012) 16(5):284–7. doi: 10.1089/omi.2011.0118
31. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two Subsets of Memory T Lymphocytes With Distinct Homing Potentials and Effector Functions. *Nature* (1999) 401(6754):708–12. doi: 10.1038/44385
32. Gerlach C, Moseman EA, Loughhead SM, Alvarez D, Zwijnenburg AJ, Waanders L, et al. The Chemokine Receptor CX3CR1 Defines Three Antigen-Experienced CD8 T Cell Subsets With Distinct Roles in Immune Surveillance and Homeostasis. *Immunity* (2016) 45(6):1270–84. doi: 10.1016/j.immuni.2016.10.018
33. Pace L, Goudot C, Zueva E, Gueguen P, Burgdorf N, Waterfall JJ, et al. The Epigenetic Control of Stemness in CD8(+) T Cell Fate Commitment. *Science* (2018) 359(6372):177–86. doi: 10.1126/science.aah6499
34. Sarkar S, Kalia V, Haining WN, Konieczny BT, Subramaniam S, Ahmed R. Functional and Genomic Profiling of Effector CD8 T Cell Subsets With Distinct Memory Fates. *J Exp Med* (2008) 205(3):625–40. doi: 10.1084/jem.20071641
35. Zhou X, Yu S, Zhao DM, Harty JT, Badovinac VP, Xue HH. Differentiation and Persistence of Memory CD8+ T Cells Depend on T Cell Factor 1. *Immunity* (2010) 33(2):229–40. doi: 10.1016/j.immuni.2010.08.002
36. Martin MD, Badovinac VP. Defining Memory CD8 T Cell. *Front Immunol* (2018) 9(NOV):1–10. doi: 10.3389/fimmu.2018.02692
37. Wolint P, Betts MR, Koup RA, Oxenius A. Immediate Cytotoxicity But Not Degranulation Distinguishes Effector and Memory Subsets of CD8+ T Cells. *J Exp Med* (2004) 199(7):925–36. doi: 10.1084/jem.20031799
38. Jeannot G, Boudousquière C, Gardiol N, Kang J, Huelsken J, Held W. Essential Role of the Wnt Pathway Effector Tcf-1 for the Establishment of Functional CD8 T Cell Memory. *Proc Natl Acad Sci USA* (2010) 107(21):9777–82. doi: 10.1073/pnas.0914127107
39. Pais Ferreira D, Silva JG, Wyss T, Fuertes Marraco SA, Scarpellino L, Charmoy M, et al. Central Memory CD8+ T Cells Derive From Stem-Like Tcf7hi Effector Cells in the Absence of Cytotoxic Differentiation. *Immunity* (2020) 53(5):985–1000.e11. doi: 10.1016/j.immuni.2020.09.005
40. Lin WHW, Nish SA, Yen B, Chen YH, Adams WC, Kratchmarov R, et al. CD8+ T Lymphocyte Self-Renewal During Effector Cell Determination. *Cell Rep* (2016) 17(7):1773–82. doi: 10.1016/j.celrep.2016.10.032
41. Alfei F, Kanev K, Hofmann M, Wu M, Ghoneim HE, Roelli P, et al. TOX Reinforces the Phenotype and Longevity of Exhausted T Cells in Chronic Viral Infection. *Nature* (2019) 571(7764):265–9. doi: 10.1038/s41586-019-1326-9
42. Huster KM, Koffler M, Stemberger C, Schiemann M, Wagner H, Busch DH. Unidirectional Development of CD8+ Central Memory T Cells Into Protective Listeria-specific Effector Memory T Cells. *Eur J Immunol* (2006) 36(6):1453–64. doi: 10.1002/eji.200635874
43. Bachmann MF, Wolint P, Schwarz K, Jäger P, Oxenius A. Functional Properties and Lineage Relationship of CD8+ T Cell Subsets Identified by Expression of IL-7 Receptor Alpha and CD62L. *J Immunol* (2005) 175(7):4686–96. doi: 10.4049/jimmunol.175.7.4686
44. Kavazović I, Lenartić M, Jelenčić V, Jurković S, Lemmermann NAW, Jonjić S, et al. NKG2D Stimulation of CD8+ T Cells During Priming Promotes Their Capacity to Produce Cytokines in Response to Viral Infection in Mice. *Eur J Immunol* (2017) 47(7):1123–35. doi: 10.1002/eji.201646805
45. Wensveen FM, Lenartić M, Jelenčić V, Lemmermann NAW, ten Brinke A, Jonjić S, et al. NKG2D Induces Mcl-1 Expression and Mediates Survival of CD8 Memory T Cell Precursors Via Phosphatidylinositol 3-Kinase. *J Immunol* (2013) 191(3):1307–15. doi: 10.4049/jimmunol.1300670
46. Zloza A, Kohlhapp FJ, Lyons GE, Schenkel JM, Moore TV, Lacey AT, et al. NKG2D Signaling on CD8 + T Cells Represses T-bet and Rescues CD4-unhelped CD8 + T Cell Memory Recall But Not Effector Responses. *Nat Med* (2012) 18(3):422–8. doi: 10.1038/nm.2683
47. Ziegler H, Thale R, Lucin P, Muranyi W, Flohr T, Hengel H, et al. A Mouse Cytomegalovirus Glycoprotein Retains MHC Class I Complexes in the ERGIC/cis-Golgi Compartments. *Immunity* (1997) 6(1):57–66. doi: 10.1016/S1074-7613(00)80242-3
48. Wherry EJ, Puorro KA, Porgador A, Eisenlohr LC. The Induction of Virus-Specific CTL as a Function of Increasing Epitope Expression: Responses Rise Steadily Until Excessively High Levels of Epitope are Attained. *J Immunol* (1999) 163(7):3735–45.
49. Wherry EJ, McElhaugh MJ, Eisenlohr LC. Generation of CD8 + T Cell Memory in Response to Low, High, and Excessive Levels of Epitope. *J Immunol* (2002) 168(9):4455–61. doi: 10.4049/jimmunol.168.9.4455
50. Torti N, Walton SM, Murphy KM, Oxenius A. Batf3 Transcription Factor-Dependent DC Subsets in Murine CMV Infection: Differential Impact on T-cell Priming and Memory Inflation. *Eur J Immunol* (2011) 41(9):2612–8. doi: 10.1002/eji.201041075
51. Busche A, Jirmo AC, Welten SPM, Zischke J, Noack J, Constabel H, et al. Priming of CD8 + T Cells Against Cytomegalovirus-Encoded Antigens Is Dominated by Cross-Presentation. *J Immunol* (2013) 190(6):2767–77. doi: 10.4049/jimmunol.1200966
52. Stempel M, Chan B, Jurančić Lisnić V, Krmptović A, Hartung J, Paludan SR, et al. The Herpesviral Antagonist m152 Reveals Differential Activation of STING -Dependent IRF and NF - $\kappa$ B Signaling and STING 'S Dual Role During MCMV Infection. *EMBO J* (2019) 38(5):1–22. doi: 10.15252/emboj.2018100983
53. Crouse J, Kalinke U, Oxenius A. Regulation of Antiviral T Cell Responses by Type I Interferons. *Nat Rev Immunol* (2015) 15(4):231–42. doi: 10.1038/nri3806
54. Welten SPM, Yermanos A, Baumann NS, Wagen F, Oetiker N, Sandu I, et al. Tcf1+ Cells are Required to Maintain the Inflammatory T Cell Pool Upon MCMV Infection. *Nat Commun* (2020) 11(1):1–14. doi: 10.1038/s41467-020-16219-3
55. Henning AN, Roychoudhuri R, Restifo NP. Epigenetic Control of CD8+ T'cell Differentiation. *Nat Rev Immunol* (2018) 18(5):340–56. doi: 10.1038/nri.2017.146
56. Tomić A, Varanasi PR, Golemac M, Malić S, Riese P, Borst EM, et al. Activation of Innate and Adaptive Immunity by a Recombinant Human

Cytomegalovirus Strain Expressing an NKG2D Ligand. *PLoS Pathog* (2016) 12 (12):1–27. doi: 10.1371/journal.ppat.1006015

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Šustić, Cokarić Brdovčak, Lisnić, Materljan, Juranić Lisnić, Rožmanić, Indenbirken, Hiršl, Busch, Brizić, Krmpotić and Jonjić. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.